William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP
Professor of Medicine, Physiology, and Cell Biology
Chair of Excellence in Cardiovascular Medicine
Director, Division of Cardiovascular Medicine
Associate Dean for Clinical Research
Deputy Director, Davis Heart and Lung Research Institute
The Ohio State University
Additional Content Development Faculty
Jill M. Gelow, MD, MPH
Assistant Professor of Medicine, Heart Failure and Transplant Cardiology
Program Director, Cardiovascular Disease Fellowship
Program Director, Advanced Heart Failure and Transplant Fellowship
Knight Cardiovascular Institute
Oregon Health and Science University
Stuart D. Russell, MD
Associate Professor of Medicine
Medical Director, Heart Failure and Transplantation
Johns Hopkins Hospital
Alan B. Storrow, MD
Vice Chairman for Research and Academic Affairs
Department of Emergency Medicine
1.0 AMA PRA Category 1 CreditTM
Each year, more than 1 million individuals are hospitalized for heart failure (HF). Within the spectrum of HF, acute heart failure (AHF) represents a distinct challenge to clinicians. Diagnosis of AHF is often delayed because of the complex characteristics of the condition. The heterogeneous nature of AHF patients and the presence of comorbid conditions can make it difficult for clinicians to recognize the signs of AHF and provide optimal treatment. Mortality and readmission rates for patients with AHF remain high because hospital clinicians do not consistently adhere to guidelines for AHF management, discharge support, and education. This activity will outline strategies for optimal diagnosis and management of this disease.
This activity is intended for cardiologists, emergency physicians, hospitalists, primary care physicians, physician assistants, nurse practitioners, and nurses.
Upon completion of this educational activity, the participant should be able to:
- Describe recent advances to help hospital-based clinicians more accurately diagnose and risk stratify patients with AHF.
- Incorporate risk stratification into ED admission/discharge decisions.
- Follow ACCF/AHA-recommended strategies for achieving GDMT, including up-titration, dose adjustment, and monitoring strategies.
- Describe current safety and efficacy data on emerging investigational therapies for AHF in late stages of clinical development.
- Identify strategies to increase collaboration among members of the clinical team during and after hospitalization to reduce re-hospitalization rates.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Dr. Abraham has disclosed the following:
Consultant: Novartis; Abbott Vascular; St. Jude Medical, Inc.
Dr. Gelow has no conflicts of interest to disclose.
Dr. Russell has disclosed the following:
Consultant: Thoratec Corporation
Dr. Storrow has disclosed the following:
Consultant: Trevena, Inc.
Penn State staff involved in the development and review of this activity have nothing to disclose.
Lily McVey, MCM Education writer/editor, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
Credit is awarded to participants who score 70% or better on the post-test.
The online activity will take approximately 60 minutes to complete.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5887-16-T.
Commercial Support Statements
Supported by an independent educational grant from Novartis.
- There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.
- Review the intended audience, learning objectives, and author disclosures.
- Study the educational content online.
- Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
- Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, or Novartis. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.